GLRX5 and liver cancer: As was shown in Figure 7, Kaplan-Meier (KM) plotter survival analysis, based on clinical information from the TCGA liver cancer datasets, revealed that the low expression of BIRC2 (HR = 0.67, 95% CI: 0.46-0.96, and P = 0.028, Figure 7(c)), BCKDHA (HR = 0.5, 95% CI: 0.34-0.74, and P = 0.00031, Figure 7(d)), PMPCB (HR = 0.69, 95% CI: 0.49-0.99, and P = 0.042, Figure 7(e)), and GLRX5 (HR = 0.7, 95% CI: 0.5-1, and P = 0.046, Figure 7(f)) significantly correlated with shorter OS of LIHC patients.